Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
90.89(c) 91.19(c) 91.48(c) 90.53(c) 89.87(c) Last
486 325 787 167 1 037 528 1 706 495 1 290 223 Volume
+0.84% +0.33% +0.32% -1.04% -0.73% Change
More quotes
Financials ($)
Sales 2016 1 114 M
EBIT 2016 -740 M
Net income 2016 -579 M
Finance 2016 69,8 M
Yield 2016 -
Sales 2017 1 311 M
EBIT 2017 -160 M
Net income 2017 -189 M
Finance 2017 50,5 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 13,8x
EV / Sales2017 11,8x
Capitalization 15 457 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the biopharmaceutical development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.The company was founded on March 21, 1997 and... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
02/15 BIOMARIN PHARMACEUTICAL : Announces 11 Presentations at 13th Annual WORLDSymposi..
02/13 BIOMARIN PHARMACEUTICAL : The Commerzbank Aktiengesellschaft Fi Sells 7,957 Shar..
02/09 BIOMARIN PHARMACEUTICAL : Investigators at BioMarin Pharmaceutical Report Findin..
02/08 BIOMARIN PHARMACEUTICAL : to Attend Three Investor Conferences in 1Q17
02/07 BIOMARIN TO HOST FOURTH QUARTER AND : 30pm ET
02/01 BIOMARIN PHARMACEUTICAL : Receives Access to Priority Medicines (PRIME) Regulato..
01/24 The Synovus Financial Corp Sells 5,015 Shares of Biomarin Pharmaceutical Inc...
01/19 BIOMARIN PHARMACEUTICAL : Transfers Duchenne Natural History Database to CureDuc..
01/09 BIOMARIN PHARMACEUTICAL : Research Reports Initiation on Biotech Stocks -- Immun..
01/09 BIOMARIN PHARMACEUTICAL : to Provide Update to Proof-of-Concept Data for BMN 270..
More news
Sector news : Biopharmaceuticals
01:24pDJBAYER : Proposes Higher Dividend for 2016
11:58a Why TEVA Stock Has Been on a Prolonged Dive
08:48aDJBAYER : Investors Upbeat on Takeover -- WSJ
03:32a Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/20DJBAYER : Trump Backing for Bayer's Monsanto Deal Buoys Investors
More sector news : Biopharmaceuticals
Latest Tweets
01:54p$MBLY $LL $FSLR $RDUS $ONCE $SPLK $FIT $IPHS $JCP $IDCC $TSLA $SINA $WB $CTRP..
1
02/18$CELG $BIIB $VRTX $BMRN $IBB $XBI Biotech 2017 | 4 Ideas for A Stockpicker’s..
15
02/18BioMarin Pharmaceutical Inc. $BMRN Short Interest Down 14.6% in January  
02/15$BMRN BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017..
1
02/14#Biotech beat: $BMRN sues to stop generic version of its $90K-a-year drug  
More tweets
Qtime:75
News from SeekingAlpha
02/14 ABEONA : Preparing For Liftoff - The Next Avexis?
02/09 FDA OKs an anti-inflammatory med to treat Duchenne muscular dystrophy
02/07 Who Loves Ya, Baebies? The FDA Does
02/07 Premarket analyst action - healthcare
02/01 BioMarin's hemophilia A candidate BMN-270 nabs PRIME status in Europe
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 113 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Henry J. Fuchs Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Elaine J. Heron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICA..8.49%15 457
BIOGEN INC10.56%62 397
CSL LIMITED19.78%41 842
ALEXION PHARMACEUTICAL..5.29%28 935
GRIFOLS SA11.81%14 012
3SBIO INC2.63%2 538
More Results